23084-35-7

Usage

Uses

Used in Research Applications:
6-Methoxyindole-3-acetonitrile is used as a research compound for various scientific studies and experiments. It is particularly valuable in the fields of organic chemistry, medicinal chemistry, and materials science, where it can be utilized to investigate the properties and potential applications of indole-based compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 6-Methoxyindole-3-acetonitrile is used as a key intermediate in the synthesis of various drugs and drug candidates. Its unique chemical structure allows for the development of new therapeutic agents with potential applications in the treatment of various diseases and medical conditions.
Used in Dye Production:
6-Methoxyindole-3-acetonitrile is also used in the production of dyes, where its indole-based structure contributes to the color and properties of the final product. This makes it a valuable component in the formulation of dyes for various applications, such as textiles, plastics, and printing inks.
Used in Material Science:
In the field of material science, 6-Methoxyindole-3-acetonitrile is used as a component in the development of new materials with unique properties. Its indole-based structure can be incorporated into the design of advanced materials, such as organic semiconductors, sensors, and other functional materials, to enhance their performance and expand their potential applications.

InChI:InChI=1/C11H10N2O/c1-14-9-2-3-10-8(4-5-12)7-13-11(10)6-9/h2-3,6-7,13H,4H2,1H3

Upstream product

• 3189-13-7 6-methoxylindole 
• 62467-65-6 1-(6-methoxy-1H-indol-3-yl)-N,N-dimethylmethanamine 
• 143-33-9 sodium cyanide 
• 109507-20-2 6-methoxy-3-((trimethyl-14-azaneyl)methyl)-1H-indole iodide 
• 555-03-3 3-nitroanisole 
• 74-88-4 methyl iodide 
• 773837-37-9 sodium cyanide 
• 70555-46-3 6-methoxy-1H-indole-3-carbaldehyde 
• 6011-14-9 2-aminoacetonitrile hydrochloride 
• 7677-24-9 trimethylsilyl cyanide 
• 131424-26-5 1-benzyl 3-methyl 6-methoxyindole-1,3-dicarboxylate 
• 131424-25-4 benzyl N-hydroxy-n-(3-methoxyphenyl)carbamate 
• 131424-27-6 methyl 6-methoxy-1H-indole-3-carboxylate 
• 24171-80-0 N-(3-methoxyphenyl)hydroxylamine 

Downstream Products

• 3610-36-4 2-(6-methoxy-1H-indol-3-yl)ethanamine 
• 442-51-3 harmine 
• 486-93-1 tetrahydroharmine 
• 123380-87-0 6-methoxy-1H-indole-3-acetic acid methyl ester 
• 103986-22-7 2-(6-methoxy-1H-indol-3-yl)acetic acid 

Relevant academic research and scientific papers

Tryptamine Synthesis by Iron Porphyrin Catalyzed C?H Functionalization of Indoles with Diazoacetonitrile

The functionalization of C?H bonds with non-precious metal catalysts is an important research area for the development of efficient and sustainable processes. Herein, we describe the development of iron porphyrin catalyzed reactions of diazoacetonitrile with N-heterocycles yielding important precursors of tryptamines, along with experimental mechanistic studies and proof-of-concept studies of an enzymatic process with YfeX enzyme. By using readily available FeTPPCl, we achieved the highly efficient C?H functionalization of indole and indazole heterocycles. These transformations feature mild reaction conditions, excellent yields with broad functional group tolerance, can be conducted on gram scale, and thus provide a unique streamlined access to tryptamines.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of BAF complex related disorders.

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI50 1.5 μM). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day.

New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations

Members of the kinesin superfamily are involved in key functions during intracellular transport and cell division. Their involvement in cell division makes certain kinesins potential targets for drug development in cancer chemotherapy. The two most advanc

Use of derivatives of indoles for the treatment of cancer

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.

Synthesis of indolyl-3-acetonitrile derivatives and their inhibitory effects on nitric oxide and PGE2 productions in LPS-induced RAW 264.7 cells

Arvelexin is one of major constituents of Brassica rapa that exerts anti-inflammatory activities. Several indolyl-3-acetonitrile derivatives were synthesized as arvelexin analogs and evaluated for their abilities to inhibit NO and PGE2 productions in LPS-induced RAW 264.7 cells. Of the indolyl-3-acetonitriles synthesized, compound 2k, which possesses a hydroxyl group at C-7 position of the indole ring and an N-methyl substituent, more potently inhibited NO and PGE2 productions and was less cytotoxic than arvelexin on macrophage cells.

Use of derivatives of indoles for the treatment of cancer

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.

Synthetic Approaches to Indolo[6,7-α]pyrrolo[3,4-c]carbazoles: Potent Cyclin D1/CDK4 Inhibitors

Synthesis of indolo[6,7-α]pyrrolo[3,4-c]carbazoles 1, a new class of cyclin D1/CDK4 inhibitors, by oxidation of the corresponding aryl indolylmaleimides 2, will be described. Two approaches to the synthesis of 2 were identified that required new methods f

Tandem Michael Addition-Sigmatropic Rearrangement Processes. Part 2. Construction of Cyclopropapyrroloindol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065

Development of an alternative strategy for preparing 3-acetoxymethyl-2,3-dihydro-1-methylsulfonyl-6-methoxyindole 25 has been completed.Since 25 was an intermediate in a previous synthesis of the CPI unit 5 of the antitumour antibiotic CC-1065 1, this ach